- Home
- GOVX vs BYAH Comparison
GOVX vs BYAH Comparison
Compare GOVX & BYAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOVX | BYAH |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.6M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | GOVX | BYAH |
|---|---|---|
| Price | $2.77 | $0.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $103.00 | N/A |
| AVG Volume (30 Days) | 194.5K | ★ 233.1K |
| Earning Date | 11-13-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,353,560.00 | $2,768,120.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.52 | ★ 42.65 |
| 52 Week Low | $2.61 | $0.14 |
| 52 Week High | $53.73 | $41.49 |
Technical Indicators
Market Signals| Indicator | GOVX | BYAH |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 24.17 |
| Support Level | $2.72 | $0.15 |
| Resistance Level | $3.42 | $0.17 |
| Average True Range (ATR) | 0.39 | 0.01 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 61.95 | 5.30 |
Price Performance
Historical ComparisonAbout GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.